Tissue-resident memory T cells in immune-related adverse events: friend or foe?
Robin Reschke, Thomas F. Gajewski
Abstract
Many cancer patients experience toxicity during checkpoint blockade immunotherapy, which often leads to treatment discontinuation. To this end, understanding the mechanisms mediating immune-related adverse events (irAE) should ultimately enable improvement in clinical outcomes. Recent work has revealed that tissue-resident memory T (TRM) cells are locally expanded in irAE-dermatitis and -colitis.
Topics & Concepts
DiscontinuationAdverse effectMedicineBlockadeImmune systemImmunotherapyImmune checkpointColitisImmunosurveillanceImmunologyInternal medicineReceptorT-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmune Cell Function and Interaction